Affordable Access

Publisher Website

United in Fight against prOstate cancer (UFO) registry: first results from a large, multi‐centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia

  • Uemura, Hirotsugu1
  • Ye, Dingwei2
  • Kanesvaran, Ravindran3
  • Chiong, Edmund4
  • Lojanapiwat, Bannakij5
  • Pu, Yeong‐Shiau6
  • Rawal, Sudhir Kumar7
  • Abdul Razack, Azad Hassan8
  • Zeng, Hao9
  • Chung, Byung Ha10
  • Md Yusoff, Noor Ashani11
  • Ohyama, Chikara12
  • Kim, Choung Soo13
  • Leewansangtong, Sunai14
  • Tsai, Yuh‐Shyan15
  • Liu, Yanfang16
  • Liu, Weiping17
  • van Kooten Losio, Maximiliano18, 19
  • Asinas‐Tan, Marxengel20
  • 1 Kindai University, Japan , (Japan)
  • 2 Fudan University Shanghai Cancer Center, China , (China)
  • 3 National Cancer Centre, Singapore , (Singapore)
  • 4 National University Health System, Singapore , (Singapore)
  • 5 Chiang Mai University, Thailand , (Thailand)
  • 6 National Taiwan University Hospital, Taiwan , (Taiwan)
  • 7 Rajeev Gandhi Cancer Institute, India , (India)
  • 8 University of Malaya, Malaysia , (Malaysia)
  • 9 Sichuan University, China , (China)
  • 10 Yonsei University College of Medicine, Korea , (South Korea)
  • 11 Hospital Kuala Lumpur, Malaysia , (Malaysia)
  • 12 Hirosaki University Graduate School of Medicine, Japan , (Japan)
  • 13 University of Ulsan College of Medicine, South Korea , (South Korea)
  • 14 Mahidol University, Thailand , (Thailand)
  • 15 National Cheng Kung University, Taiwan , (Taiwan)
  • 16 Johnson & Johnson, USA , (United States)
  • 17 Janssen Research and Development, China , (China)
  • 18 Janssen Medical Affairs, Asia Pacific, Australia , (Australia)
  • 19 Celgene International, Switzerland , (Switzerland)
  • 20 Janssen Medical Affairs, Asia Pacific, Singapore , (Singapore)
Published Article
British Journal of Urology
Wiley (Blackwell Publishing)
Publication Date
Jan 30, 2020
DOI: 10.1111/bju.14980
PMID: 31868997
PMCID: PMC7187217
PubMed Central
External links


Objectives To document the management of advanced prostate cancer including diagnosis, prognosis, treatment, and care, in real‐world practice in Asia using the United in Fight against prOstate cancer (UFO) registry. Patients and Methods We established a multi‐national, longitudinal, observational registry of patients with prostate cancer presenting to participating tertiary care hospitals in eight Asian countries. A total of 3636 eligible patients with existing or newly diagnosed high‐risk localised prostate cancer (HRL), non‐metastatic biochemically recurrent prostate cancer (M0), or metastatic prostate cancer (M1), were consecutively enrolled and are being followed‐up for 5 years. Patient history, demographic and disease characteristics, treatment and treatment decisions, were collected at first prostate cancer diagnosis and at enrolment. Patient‐reported quality of life was prospectively assessed using the European Quality of Life‐five Dimensions, five Levels (EQ‐5D‐5L) and Functional Assessment of Cancer Therapy for Prostate Cancer questionnaires. In the present study, we report the first interim analysis of 2063 patients enrolled from study start (15 September 2015) until 18 May 2017. Results Of the 2063 enrolled patients, 357 (17%), 378 (19%), and 1328 (64%) had HRL, M0 or M1 prostate cancer, respectively. The mean age at first diagnosis was similar in each group, 56% of all patients had extracapsular extension of their tumour, 28% had regional lymph node metastasis, and 53% had distant metastases. At enrolment, 62% of patients had at least one co‐morbidity (mainly cardiovascular disease or diabetes), 91.8% of M1 patients had an Eastern Cooperative Oncology Group performance score of <2 and the mean EQ‐5D‐5L visual analogue score was 74.6–79.6 across cohorts. Treatment of M1 patients was primarily with combined androgen blockade (58%) or androgen‐deprivation therapy (either orchidectomy or luteinising hormone‐releasing hormone analogues) (32%). Decisions to start therapy were mainly driven by treatment guidelines and disease progression. Decision to discontinue therapy was most often due to disease progression (hormonal drug therapy) or completion of therapy (chemotherapy). Conclusion In the UFO registry of advanced prostate cancer in Asia, regional differences exist in prostate cancer treatment patterns that will be explored more deeply during the follow‐up period; prospective follow‐up is ongoing. The UFO registry will provide valuable descriptive data on current disease characteristics and treatment landscape amongst patients with prostate cancer in Asia.

Report this publication


Seen <100 times